The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | The central role of BcR signaling in the pathogenesis of CLL
Massimo Degano, PhD, Fondazione Centro San Raffaele, Milan, Italy, discusses B-cell receptor (BcR) signaling in the pathophysiology of chronic lymphocytic leukemia (CLL). He mentions the value of developing drugs that target BcR signaling, which is at the root of CLL development, and the importance of understanding how cells behave in individual patients to move towards personalized medicine. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
